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Abstract
Purpose Patients with advanced cancer typically demonstrate
sharp deterioration in physical function and psychological sta-
tus during the last months of life. This study evaluates the
relationship between survival in patients with advanced can-
cer and longitudinal assessment of anxiety, depression, fa-
tigue, pain interference, and/or physical function using the
US National Institute of Health Patient Reported Outcomes
Information System.
Methods Mixed-effects models were used to evaluate patient-
reported outcome trajectories over time among patients with
advanced loco-regional or metastatic cancer receiving care in
a hospital-based palliative care clinic. Cox regression analysis
was used to assess the statistical significance of differences in
the probability of survival associated with patient-reported
outcome scores.
Results A total of 472 patients completed 1992 assessments
during the 18-month study period. Longitudinal scores for
fatigue, pain interference, and physical function demonstrated
statistically significant non-linear trajectories. Scores for de-
pression, fatigue, pain interference, and physical function
were highly statistically significant predictors of survival
(p < 0.01). Clinically meaningful differences in the probability
of survival were demonstrated between patients with scores at
the 25th vs. 75th percentiles, with absolute differences in sur-
vival at 6 and 12 months after assessment from 10 to 18
percentage points.
Conclusions Patient-reported outcomes can be used to reli-
ably estimate where patients are along the trajectory of dete-
riorating health status leading toward the end of life, and for
identifying patients with declining symptoms in need of refer-
ral to palliative care or more aggressive symptom
management.
Keywords Cancer . EHR . PROMIS
Introduction
Patients with advanced cancer have an illness trajectory that
typically begins with a period of relatively preserved function-
al status followed by a period of marked deterioration and
increased symptoms during the last months of life [1–3]. This
period of functional decline is associated with frequent hospi-
talization and increased costs of care. Analysis of Medicare
data for patients who died with poor-prognosis cancers indi-
cates that 65 % were hospitalized and 25 % had intensive care
unit stays within 30 days of their death [4].
Early identification of patients who are approaching the
end of life can improve patient outcomes by improving clin-
ical decision-making. Earlier referral to hospice and palliative
care can result in improvements in quality of life and even
length of life [5–7]. Aggressive anticancer treatment in the
terminal phase increases costs of care, may reduce quality of
life, and may fail to yield any improvement in survival [8].
Between 20 and 50 % of patients with advanced cancer re-
ceive chemotherapy within 30 days of death [9]. Patients with
systemic chemotherapy in the last months of life have a
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substantially increased risk of dying in an intensive care unit
[10]. Chemotherapy in the last weeks of life is also associated
with reduced likelihood of receiving hospice care [11].
Patient self-reported health status measures are useful for
estimating survival in cancer patients and can provide unique
information of importance for monitoring patient health status
trajectories [12–15]. While numerous patient-reported out-
come measures have been developed over the years, recent
national efforts have produced standardized assessment mea-
sures. Beginning in 2004, the National Institutes of Health
sponsored the development of the Patient-Reported Outcomes
Measurement Information System (PROMIS) to provide a
uniform methodology for quantifying physical, mental, and
social health across patient populations [16, 17]. The
PROMIS project measures provide reliable and valid assess-
ment of patient self-reported health status for use in cancer
patient care delivery and clinical research [18, 19]. This anal-
ysis examines the relationship between survival and PROMIS
domain measures among patients with advanced cancer at a
large health system and provides evidence regarding their po-
tential utility in identifying those with declining symptoms in
need of referral to palliative care or more aggressive symptom
management.
Methods
Computer-based assessment of patient-reported outcomes
(PROs) was implemented for patients with advanced loco-
regional or metastatic cancer (stage 4 solid tumor or other
advanced cancer identified as incurable by the referring on-
cologist or surgeon) who were referred to this program at the
University of Virginia Health System Cancer Center. Pallia-
tive care services include an outpatient clinic located in the
cancer center, inpatient consultation, a palliative care unit, and
home hospice components. Patients referred to this clinic are
typically followed concurrently with medical oncology, radi-
ation oncology, and surgical oncology for symptom manage-
ment and end of life care planning. The palliative care clinic
staff includes RNs, MDs and NPs, with available social work-
er and chaplaincy services.
Assessment was initiated for all patients beginning in Oc-
tober 2013, following a pilot testing phase completed in Feb-
ruary 2013 [20]. The set of PRO measures collected for each
patient was selected based on national recommendations and
physician and patient stakeholder review [21]. The assessment
includes five PROMIS health domains: anxiety, depression,
fatigue, pain interference, and physical function. Additional
PROs were developed for the project to address the following
cancer-specific symptoms: bowel function, nausea, vomiting,
anorexia, dyspnea, and peripheral neuropathy.
Patient data available from the health system Electronic
Health Record (EHR) and from health system administrative
records was collected to identify patient demographics, cancer
diagnoses, and survival outcomes for all patients with assess-
ments. Cancer diagnoses were identified using ICD-9-CM
diagnosis codes reported in hospital and outpatient care en-
counter summaries for events occurring up to 2 years prior to
the date of the first assessment. Individual ICD-9-CM codes
were grouped into categories of site-specific cancer diagnoses
using the criteria of the Agency for Healthcare Research and
Quality Clinical Classification System [22].
The collection of PROs was implemented using software
integrated within the patient’s electronic health record. The
assessment software was accessed by patients through an on-
line browser using a tablet computer. The assessment protocol
included instructions on the assessment process and on the use
of the tablet computer, which was provided by the clinic staff
to patients at each visit. Direct assistance with the assessment
process was provided by clinical staff to any patient who re-
quested assistance. Patients completed an assessment at each
routine follow-up appointment, before their clinical encounter.
The availability of direct assistance with the assessment was
included in the protocol based on the results of the pilot study,
which demonstrated that while most patients were able to
complete the assessment without assistance, some patients
required direct assistance with the use of the tablet computer,
with the assessment software, or with the assessment ques-
tions [20].
Completed assessments were posted immediately to the
patients’ EHR records. Displays of both current and longitu-
dinal results were available during the patient encounter for
use in therapeutic decision-making, assessment of response to
treatment, symptom management, and end of life care plan-
ning. This analysis includes results collected for the five
PROMIS health domains during the 18-month period from
October 2013 through March 2015.
Each PROMIS domain was scored using the version 1.0
short form item series, with 5 ordinal response options (1 to 5)
for each question in the domain [23]. Mean scores for the total
responses indicate whether patients have more or less of the
domain being measured. For example, higher mean scores
indicate worse anxiety, depression, fatigue, and pain interfer-
ence, but better physical function. Mean scores were calculat-
ed for each domain, for each patient assessment. Mean scores
were also calibrated to the weighted distribution of mean
scores from a large representative sample of the US general
population, using the BT-score^ algorithm [24]. Population-
calibrated scores are referent to the surveyed population mean
of 50 and standard deviation of 10, such that a patient with a T-
score of 40 in the study population has a score that is one
standard deviation below the US general population mean.
Frequency distributions for PROMIS domain score values
were calculated at the mean score scale and T-score scale.
Patients in the study population were referred at differ-
ent points in time in the progression of their disease.
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Given this heterogeneity in stage of disease progression
among patients, there was no shared reference point for
defining the start point of trajectory patterns measured
prospectively in the total study population. Rather, trajec-
tory patterns were assessed retrospectively for deceased
patients only, using the patient’s date of death as a shared
reference point for the end of the trajectory.
Multi-level mixed-effects models were used to estimate
the significance and direction of PROMIS domain score
trajectories over time. Differences among patients in the
number of assessments and in the spacing between assess-
ments prior to death are accommodated by the hierarchi-
cal structure of these models [25]. The shape of the score
trajectories was estimated using linear, quadratic, and
spline functions. Linear models estimate only the linear
association between scores and months prior to death.
Quadratic models have components for estimating both
the linear and non-linear association. Spline functions
are piecewise polynomials with components that combine
into curved functions fit to the pattern of scores. Spline
functions yield maximum precision for estimation of non-
linear relationships [26]. The statistical significance of
each functional relationship was assessed using the fixed
effect F-test statistic p value calculated for each model
parameter. The extent of non-linearity in the relationship
between PROMIS scores and months prior to death was
measured using the Akaike information criterion (AIC)
statistic to calculate the probability of information loss
from excluding non-linear relationships in the models
[27].
Cox regression analysis was used to assess the statistical
significance of differences in the probability of survival by
months post assessment associated with PROMIS domain
scores for all patients in the study population. The statistical
significance of the model score coefficients was assessed
using the Wald chi-square test statistic. Survival probabilities
at the time of assessment were estimated using models with
time-dependent covariates conditional on the interaction be-
tween the PROMIS domain score and the number of months
elapsed since the beginning of follow-up [28–30]. A logarith-
mic function was used to represent the non-linear shape of
change in scores over time [31]. Probabilities of survival at 6
and 12 months post assessment were estimated with reference
to the 25th, 50th, and 75th percentiles of the domain score
distributions. The statistical significance of the difference in
survival by quartiles of the PROMIS domain scores was cal-
culated using the stratified log-rank test statistic.
Data management, statistical programming, and graphics
programming was conducted using SAS 9.4 and R statistical
software, version 2.13 (R foundation for Statistical Comput-
ing, Vienna, Austria). The statistical significance of parameter
effect estimates and of test statistics was assessed at the a priori
threshold value of p < 0.01.


















Private/commercial health insurance 169 35.81
Self-pay 20 4.24




Age in years at referral 58.9 12.15
Site-specific cancer diagnosis groups
Bronchus, lung 82 17.37
Breast 69 14.62
Head and neck 56 11.86
Ovary 43 9.11
Other GI organs; peritoneum 42 8.90
Colon 40 8.47
Other non-epithelial cancer of skin 40 8.47
Bone and connective tissue 35 7.42
Brain and nervous system 33 6.99
Uterus 30 6.36
Other female genital organs 29 6.14
Rectum and anus 28 5.93
Melanomas of skin 27 5.72
Cervix 26 5.51
Prostate 23 4.87
Liver and intrahepatic bile duct 22 4.66
Kidney and renal pelvis 21 4.45
Pancreas 20 4.24
Benign neoplasm of uterus 19 4.03
Non-Hodgkin’s lymphoma 15 3.18
Bladder 11 2.33





Multiple myeloma 5 1.06
Hodgkin’s disease 2 0.42
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Results
All patients presenting in the clinic who met the selection
criteria were included in the study, and all selected pa-
tients were able to complete the assessments. A total of
472 patients completed assessments during the 18-month
study period, and 203 of these patients (43 %) died during
the study period. Demographic and diagnostic character-
istics of the study population are listed in Table 1. The
mean age was 58.9 years, and 56.6 % of patients were
female. Cancer of the bronchus and lung (17.4 %), breast
(14.6 %), head and neck (11.9 %), ovary (9.1 %), colon
(8.5 %), and other cancers for gastro-intestinal sites and
peritoneum (8.9 %) were the most frequently occurring
cancer sites reported for the study population.
A total of 1992 assessments were completed during the
study period, with repeated assessments available for most
patients: >1 (73.3 %), >2 (55.1 %), >3 (41.5 %). The mean
number of assessments per patient was 4.2, with a mean of
3.8 months between assessments. Figure 1 illustrates the pat-
terns of consecutive scores reported for three example patients
who died during the study period.
Table 2 lists the distributional characteristics of the
PROMIS mean domain scores and the T-score scaled
mean domain scores in the study population. The T-
score scaled results demonstrate that patients in the
study population had overall score means that were
higher than the US general population medians for anx-
iety (56.8), depression (51.9), fatigue (56.0), and pain
interference (58.1) and had lower mean scores for phys-
ical function (44.4).
Table 2 also displays the multi-level mixed-effects
model analysis results for functional trends in scores
during the months prior to death. Statistically significant
linear relationships were demonstrated for fatigue, pain
interference, and physical function scores. Linear trends
in anxiety and depression scores were not statistically
significant. Statistically significant non-linear trends
were demonstrated by the quadratic model for fatigue,
pain interference, and physical function scores. Quadrat-
ic model terms were not significant for trends in anxiety
scores (p = 0.4207, p = 0.5055) and were near signifi-
cance for trends in depression scores (p = 0.0599,
p = 0.0545) over the months preceding death. The
spline models demonstrate that non-linear function com-
ponents were significant or nearly significant for each
of the five PROMIS score domains. Figure 2 illustrates
the shapes of the estimated spline model trajectories for
each PROMIS score domain among the deceased pa-
tients. Non-linear functional transformations using the
Fig. 1 A plot of example assessment score values reported for three
patients who died during the study period, for each PROMIS domain.
Dates of assessment are indexed by months prior to death along the
horizontal access, and mean domain score values reported for each
assessment are represented on the vertical axis. Consecutive scores for
example patients are linked by reference lines, for each of the three
example patients identified in the plot legend
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spline models significantly improved the fit of trajecto-
ries estimated for the depression, fatigue, pain interfer-
ence, and physical function scores. The probability of
information loss associated with excluding non-linear
terms was 1.0 for each of these four PROMIS domains.
Figure 3 presents plots of the exact functional rela-
tionships over time for scores at the 25th, 50th, and
75th percentile reference values of each of the five
PROMIS domain score distributions. Reference values
for the mean score and T-score values corresponding
to the 25th, 50th, and 75th percentiles of each PROMIS
domain score distribution are listed in Table 2. Results
for the stratified log-rank test statistic demonstrate that
the differences in survival functions by quartiles of the
anxiety and depression scores were not statistically sig-
nificant. However, highly statistically significant differ-
ences in survival were demonstrated for quartiles of
scores for fatigue, pain interference, and physical func-
tion (p < 0.01).
The predictive relationship of PROMIS domain
scores to post assessment survival was evaluated for
all patient assessments. Table 2 lists results obtained
from the Cox regression analysis. Each of the PROMIS
domain scores had highly statistically significant rela-
tionships to patient survival, except the PROMIS do-
main scores for anxiety (p = 0.8692). Large absolute
differences in survival at 6 and 12 months post assess-
ment occur between patients with domain scores at the
25th and 75th percentiles for fatigue, pain interference,
and physical function. Patients who reported high levels
of physical function (scores at 75th percentile) had a
0.99 probability of 6-month survival and a 0.89 proba-
bility of 12-month survival. In comparison, patients with
low levels of physical function (25th percentile) had a
Table 2 PROMIS score distributions and statistical model results
Anxiety Depression Fatigue Pain interference Physical function
Mean score scale mean 2.46 1.95 2.84 2.67 3.93
Mean score scale 25th percentile 1.75 1.00 2.25 1.66 3.30
Mean score scale 50th percentile 2.50 1.75 2.75 2.66 4.00
Mean score scale 75th percentile 3.00 2.50 3.50 3.66 4.75
T-score scale mean 56.80 51.94 55.96 58.11 44.40
T-score scale 25th percentile 52.10 38.20 51.50 53.20 38.90
T-score scale 50th percentile 58.40 53.20 55.60 59.50 43.10
T-score scale 75th percentile 62.50 58.20 61.30 64.80 49.60
Multi-level mixed-effects models (deceased patients only)
Linear model
Linear term p value 0.6367 0.8048 0.0001 0.0005 <0.0001
Quadratic model
Linear term p value 0.4207 0.0599 <0.0001 <0.0001 <0.0001
Quadratic term p value 0.5055 0.0545 0.0038 0.0018 <0.0001
Spline model
Linear term p value 0.2301 0.3679 0.4053 0.6804 0.1371
Spline term part 1 p value 0.0393 0.0236 0.3653 0.5419 0.0593
Spline term part 2 p value 0.0061 0.0008 0.0175 0.0205 0.4479
Probability of information loss by excluding non-linear terms 0.1353 1.0000 1.0000 1.0000 1.0000
Cox regression models (all patients)
Score term p value 0.8692 0.0005 <0.0001 <0.0001 <0.0001
Survival curve homogeneity over score quartiles log-rank p value 0.1033 0.0189 0.0031 <0.0001 <0.0001
Probabilities of survival
25th percentile at 6 months 0.95 0.96 0.98 0.98 0.89
50th percentile at 6 months 0.91 0.93 0.95 0.94 0.96
75th percentile at 6 months 0.94 0.92 0.91 0.90 0.99
25th percentile at 12 months 0.80 0.82 0.87 0.87 0.72
50th percentile at 12 months 0.77 0.79 0.82 0.80 0.83
75th percentile at 12 months 0.79 0.76 0.73 0.73 0.89
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0.89 probability of 6-month survival (−0.10 point differ-
ence) and a 0.72 probability of 12-month survival
(−0.17 point difference). Table 2 lists the absolute dif-
ferences in 6- and 12-month survival for patients at the
Fig. 3 A plot of the survival functions estimated for all patients in the
study population, with reference to the mean scores at the 25th, 50th, and
75th percentiles of the overall domain distributions, for each PROMIS
domain. Months post assessment are indexed on the horizontal access.
Estimated probabilities of survival are indexed on the vertical axis
Fig. 2 A plot of the spline function trajectory of estimated score values
reported for deceased patients, for each PROMIS domain. All mean score
values are plotted, with dates of assessment indexed by months prior to
death along the horizontal access, and mean domain score values
represented on the vertical axis, for each PROMIS domain. The spline
function trajectory of estimated score values is depicted by bars plotted
for each assessment date, superimposed on the scatterplot of all score
values
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25th and 75th percentiles of each of the five PROMIS
domain scores.
Discussion
This research demonstrates that PROMIS scores for fatigue,
pain interference, and physical function provide reliable indi-
cations of reduced 6- and 12-month survival in patients with
advanced cancer. In our study population, patients with scores
at the high or low ends of the scales demonstrate clinically
meaningful absolute differences in the probability of survival
at 6 and 12 months after assessment.
The PROMIS assessment tools provide a standardized and
readily available method for scoring fatigue, pain interference,
and physical function. Regular computer-based patient assess-
ment provides longitudinal information useful for informing
clinical decisions during patient visits, while ensuring that
patient data is fully protected within the EHR. When PROs
are available in routine EHR reports, patients with severe
symptoms or trend patterns of concern can be identified early
and referred to appropriate services prior to symptom escala-
tion to the point of requiring inpatient management.
Patient-reported outcomes are increasingly recognized as rel-
evant to oncology. Patient-reported outcomes provide a unique
patient perspective on treatment benefit and risk that goes be-
yond clinician-reported adverse events [32]. Patients and clini-
cians often differ in their assessment of the severity and impact
of cancer and treatment-related symptoms [33]. As a result,
PROs can provide crucial information for guiding patient care.
The Center for Medicare and Medicaid Innovation is develop-
ing new payment and delivery models for oncology care that
utilize patient-reported outcomes assessment and recommends
the use of the PROMIS short forms for this purpose [34].
In the era of increasingly shared care and shortened patient
visits, computer-based assessment of PROs can enhance the
continuity of care provided. Clinicians often must make deci-
sions using information from a snapshot in time, andwithout the
patient’s longitudinal history being available and readily acces-
sible at the point of care, it can be difficult to identify patients
with meaningful changes in these status measures. Longitudinal
PROs in the EHR are highly useful for identifying patients with
reduced probabilities of survival, and for identifying patients
with declining symptoms in need of referral to palliative care
or more aggressive symptommanagement. We hypothesize that
end of life health interventions that target reducing fatigue and
pain interference and increasing physical function are the ones
most likely to improve quality of life and prolong survival.
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